Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

34.26
-0.6900-1.97%
Post-market: 34.24-0.0200-0.06%19:53 EDT
Volume:1.74M
Turnover:59.87M
Market Cap:3.96B
PE:-10.73
High:35.46
Open:35.25
Low:33.85
Close:34.95
52wk High:43.15
52wk Low:21.21
Shares:115.55M
Float Shares:110.00M
Volume Ratio:0.76
T/O Rate:1.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1920
EPS(LYR):-3.1920
ROE:-47.34%
ROA:-30.27%
PB:6.19
PE(LYR):-10.73

Loading ...

Viking Therapeutics Completes Enrollment in Phase 3 Obesity Drug Trial

Reuters
·
Nov 19, 2025

Viking Therapeutics Announces Completion of Enrollment in Phase 3 Vanquish-1 Trial of Vk2735

THOMSON REUTERS
·
Nov 19, 2025

A Fresh Look at Viking Therapeutics (VKTX) Valuation After Recent Share Price Momentum

Simply Wall St.
·
Nov 15, 2025

Viking Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Nov 12, 2025

Viking Therapeutics Stock (VKTX) Jumps on Obesity Drug. Next Big Pharma Target?

TIPRANKS
·
Nov 11, 2025

Viking Therapeutics (VKTX): Evaluating Valuation After New Obesity Drug Data Spurs Fresh Interest

Simply Wall St.
·
Nov 08, 2025

Viking Therapeutics’ VK2735: A Promising Step Forward in Metabolic Disease Treatment Justifying a Buy Rating

TIPRANKS
·
Nov 08, 2025

Promising Potential of Viking Therapeutics’ VK2735: A Buy Rating Justified by Efficacy in Weight Loss and Metabolic Health

TIPRANKS
·
Nov 07, 2025

BRIEF-Viking Therapeutics Highlights Clinical Data From VK2735 Obesity Program In Presentation At ObesityWeek 2025

Reuters
·
Nov 06, 2025

Viking Therapeutics Highlights Clinical Data From Vk2735 Obesity Program in Presentation at Obesityweek® 2025

THOMSON REUTERS
·
Nov 06, 2025

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Benzinga_recent_news
·
Nov 05, 2025

Jim Cramer Says 'Take A Pass' On This Tech Stock, Won't Go Near Oils

Benzinga
·
Nov 05, 2025

Viking Therapeutics (VKTX) Gets a Buy from BTIG

TIPRANKS
·
Oct 31, 2025

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Reuters
·
Oct 31, 2025

Viking Therapeutics Showcases VK2735 Obesity Clinical Data at ObesityWeek 2025

Reuters
·
Oct 30, 2025

Canaccord Genuity Initiates Viking Therapeutics at Buy With $106 Price Target

MT Newswires Live
·
Oct 29, 2025

Viking Therapeutics Initiated at Buy by Canaccord Genuity

Dow Jones
·
Oct 29, 2025

Canaccord starts Viking Therapeutics with Buy on obesity potential

TIPRANKS
·
Oct 29, 2025

Viking Therapeutics Executives Unload Massive Stock Holdings!

TIPRANKS
·
Oct 29, 2025

Viking Therapeutics’ VK2735 Study: A Potential Game-Changer for Weight Management in Type 2 Diabetes

TIPRANKS
·
Oct 28, 2025